A-Sleep Signs Domestic Distribution and Sales Deal with Handok for "Sleep Rhythm Tracking" Digital Medical Device

Recording and Evaluation of Sleep with Contactless AI-Based "ChronoTrack"

A-Sleep announced on the 20th that it has signed a domestic distribution and sales agreement with Handok for "ChronoTrack," a digital medical device for tracking sleep rhythms.

Lee Dongheon, CEO of Asleep (right), and Miyeon Kim, President of Handok, are posing for a commemorative photo after signing the "ChronoTrack Domestic Distribution and Sales Agreement" on the 19th. Asleep

With this agreement, A-Sleep has commercialized ChronoTrack, a digital medical device, through pharmaceutical distribution networks, following its distribution partnership with Chong Kun Dang for the sleep apnea screening software medical device "AppnoTrack."

AppnoTrack demonstrated the market potential for prescription-based digital sleep tests by being adopted at more than 400 hospitals and clinics, and over 10 general hospitals nationwide, within just six months of its launch. Through ChronoTrack, A-Sleep plans to expand its medical device business from sleep apnea to insomnia and sleep rhythm disorders—two major areas in the field.

The number of sleep disorder patients in Korea rose by approximately 26% over the past five years, from about 1,037,000 in 2020 to about 1,308,000 in 2024. Sleep disorders are increasingly recognized as an important health management concern, as they are linked not only to inconvenience but also to an increased risk of chronic illnesses and cardiovascular diseases.

Objective assessment of sleep patterns is essential in managing sleep disorders. Until now, tools such as sleep diaries and assessments of sleep rhythm patterns have been utilized. However, sleep diaries often rely on patients' subjective records, while sleep rhythm pattern assessments have limited use in clinical settings.

ChronoTrack automatically records 14 days of sleep data based on AI analysis of breathing and movement sounds while the smartphone is placed beside the bed. Without the need for wearables or contact-based sensors, it objectively analyzes key indicators such as Total Sleep Time (TST), Sleep Efficiency (SE), Sleep Onset Latency (SoL), Wake After Sleep Onset (WASO), and Sleep Regularity Index (SRI). This enables medical professionals to more accurately evaluate patients’ conditions and continuously monitor treatment effectiveness. ChronoTrack is also eligible for non-reimbursable use under Korean health regulations, meaning it can be immediately utilized in clinical practice without separate reimbursement procedures.

Handok, responsible for distribution and sales, is expanding its business into the digital healthcare sector by leveraging its expertise and healthcare provider network developed through its prescription insomnia medicines. The company has established differentiated competitiveness in the sleep sector, including the introduction of its prescription digital therapy for insomnia, "SleepQ."

Dongheon Lee, CEO of A-Sleep, stated, "In this new era of convergence between pharmaceuticals and digital technology, accurate sleep records are the starting point for all treatments. Alongside prescription insomnia medications and digital cognitive behavioral therapy, ChronoTrack will serve as the foundation for recording and assessment, ensuring Handok’s full-cycle care system for sleep rhythm disorders is complete."

This content was produced with the assistance of AI translation services.